Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is developing JNJ-2113 (PN-235), an oral IL-23 drug targeting psoriasis, however partner Johnson & Johnson (JNJ) says that until the...
The Biden administration has so far approved over $22 billion in student loan forgiveness for borrowers who were harmed by school misconduct. And the...